- Home
- ALLK vs HLVX Comparison
ALLK vs HLVX Comparison
Compare ALLK & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- HLVX
- Stock Information
- Founded
- ALLK 2012
- HLVX 2020
- Country
- ALLK United States
- HLVX United States
- Employees
- ALLK N/A
- HLVX N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- ALLK Health Care
- HLVX Health Care
- Exchange
- ALLK Nasdaq
- HLVX Nasdaq
- Market Cap
- ALLK 101.0M
- HLVX 87.6M
- IPO Year
- ALLK 2018
- HLVX 2022
- Fundamental
- Price
- ALLK $1.10
- HLVX $1.90
- Analyst Decision
- ALLK Hold
- HLVX Hold
- Analyst Count
- ALLK 5
- HLVX 5
- Target Price
- ALLK $1.67
- HLVX $2.33
- AVG Volume (30 Days)
- ALLK 306.2K
- HLVX 245.3K
- Earning Date
- ALLK 11-06-2024
- HLVX 11-07-2024
- Dividend Yield
- ALLK N/A
- HLVX N/A
- EPS Growth
- ALLK N/A
- HLVX N/A
- EPS
- ALLK N/A
- HLVX N/A
- Revenue
- ALLK N/A
- HLVX N/A
- Revenue This Year
- ALLK N/A
- HLVX N/A
- Revenue Next Year
- ALLK N/A
- HLVX N/A
- P/E Ratio
- ALLK N/A
- HLVX N/A
- Revenue Growth
- ALLK N/A
- HLVX N/A
- 52 Week Low
- ALLK $0.54
- HLVX $1.55
- 52 Week High
- ALLK $3.36
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- ALLK 52.99
- HLVX 47.67
- Support Level
- ALLK $1.00
- HLVX $1.88
- Resistance Level
- ALLK $1.11
- HLVX $2.13
- Average True Range (ATR)
- ALLK 0.08
- HLVX 0.07
- MACD
- ALLK 0.00
- HLVX -0.01
- Stochastic Oscillator
- ALLK 47.73
- HLVX 15.56
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.